Veradermics reports FY 2025 net loss $70M; cash $141.9M; IPO raised $295M; two pivotal trials enrolled

Veradermics, Inc

FY 2025 net loss $70.0M vs $26.5M in 2024; Q4 net loss $21.8M vs $5.7M.
Cash, equivalents & marketable securities $141.9M at Dec 31, 2025; upsized IPO added $294.8M gross in Feb 2026.
R&D expenses FY 2025 $62.1M (up $38.8M YoY) driven by VDPHL01 clinical development and headcount.
Enrollment completed in Phase 2/3 Study 302 (male PHL) and confirmatory Study 304; topline data 1H and 2H 2026.
Appointed Mark Neumann as Chief Commercial & Strategy Officer; Study 306 enrolling for female PHL.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Veradermics, Inc reported financial results for the fourth quarter and year ended December 31, 2025.

Period: the fourth quarter and year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 30, 2026, Veradermics, Incorporated issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025.

View on SEC.gov

1350 earnings releases filed in the last 30 days. Browse all earnings releases →

Veradermics, Inc filing history →

Source: SEC EDGAR

accession 0001827635-26-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.